Last reviewed · How we verify
Calcium pre-treatment
Calcium pre-treatment reduces contrast-induced nephropathy by maintaining renal perfusion and reducing oxidative stress during contrast exposure.
Calcium pre-treatment reduces contrast-induced nephropathy by maintaining renal perfusion and reducing oxidative stress during contrast exposure. Used for Prevention of contrast-induced nephropathy in patients undergoing contrast-enhanced imaging or interventional procedures.
At a glance
| Generic name | Calcium pre-treatment |
|---|---|
| Sponsor | Wake Forest University Health Sciences |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
Mechanism of action
Calcium supplementation prior to contrast administration helps preserve renal function by stabilizing cellular calcium homeostasis and reducing ischemic injury to the kidney tubules. This approach is based on the hypothesis that adequate calcium levels protect against the nephrotoxic effects of iodinated contrast agents, particularly in high-risk patients with pre-existing renal impairment.
Approved indications
- Prevention of contrast-induced nephropathy in patients undergoing contrast-enhanced imaging or interventional procedures
Common side effects
- Hypercalcemia
- Gastrointestinal upset
- Constipation
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib (PHASE1)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Anastomotic Leakage Prevention by Endovascular Stenting of the Superior Mesenteric Artery (NA)
- MRI Guided Management of Occlusive Peripheral Arterial Disease
- Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer (PHASE2)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcium pre-treatment CI brief — competitive landscape report
- Calcium pre-treatment updates RSS · CI watch RSS
- Wake Forest University Health Sciences portfolio CI